News

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief ...
pharmaphorum6d
First data with subcutaneous Leqembi, and other CTAD news
Biogen’s tau antisense Biogen also reported preliminary data at CTAD from a phase 1b study of BIIB080, an antisense drug targeting tau, in 46 mild Alzheimer’s patients. There were ...
Market Inference2d
Ionis Pharmaceuticals CDO Retires, Successor Named
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has announced the retirement of Dr. Richard Geary, the current Chief Development ...